EXHIBIT 99.1

        CIPHERGEN APPOINTS STEVE LUNDY AS SENIOR VICE PRESIDENT OF SALES
                                  AND MARKETING

FREMONT, CALIF., MAY 15, 2007 - Ciphergen Biosystems, Inc. (Nasdaq: CIPH)
today announced the appointment of Steve Lundy as Senior Vice President of
Sales and Marketing.  Mr. Lundy brings nearly 20 years of experience leading
high growth sales and marketing initiatives in the diagnostics industry.

"Steve's impressive track record of successfully commercializing molecular
diagnostic tests will be invaluable as we prepare for the launch and
commercialization of several high-value tests," said Gail S. Page, President and
CEO of Ciphergen. "His experience developing marketing strategies and building
commercial teams will help us to grow our diagnostics business."

Mr. Lundy joins Ciphergen Biosystems from GeneOhm, a division of BD Diagnostics,
where he served as Vice President of Sales and Marketing since 2003. BD acquired
GeneOhm for $230 million in February 2006. While at GeneOhm, he successfully led
the commercial launch of several novel molecular diagnostic assays including the
first molecular test for Methicillin Resistant Staphylococcus Aureus (MRSA).. In
addition he helped raise $30 million in venture capital. From 2002 to 2003, Mr.
Lundy served as Vice President of Marketing for Esoterix, Inc., which was
acquired by Laboratory Corporation of America, and led the commercial
integration and re-branding of the numerous reference labs acquired by Esoterix.
Prior to Esoterix, he was Marketing Director, Molecular Diagnostics and Critical
Care Testing at Bayer Diagnostics Corporation and had marketing responsibility
for a $100 million of business in the fastest growing business segments.

"I am excited to be joining Ciphergen at this critical phase in its development
as we gear up for the launch of new products," said Mr.Lundy. "My experience in
growing successful diagnostics businesses and bringing new assays to the
marketplace will help Ciphergen achieve its mission of helping physicians
diagnose, treat and improve outcomes for patients."

Mr. Lundy holds a B.S. in Education from the United States Air Force Academy.

His appointment to Senior Vice President of Sales and Marketing will be
effective May 16, 2007.

ABOUT CIPHERGEN
Ciphergen Biosystems, Inc. is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Ciphergen, along with its
prestigious scientific collaborators, has ongoing diagnostic programs in
oncology, cardiology and women's health with an initial focus in ovarian cancer.
Based in Fremont, California, more information about Ciphergen can be found on
the Web at http://www.ciphergen.com.
Forward Looking Statements

SAFE HARBOR STATEMENT
This news release contains forward-looking statements that involve significant
risks and uncertainties, including those discussed below and others that can be
found in Ciphergen's Form 10-K for the year ended Dec. 31, 2006, and in
Ciphergen's periodic reports on Form 10-Q and Form 8-K. Ciphergen is providing
this information as of the date of this news release and does not undertake any
obligation to update any forward-looking statements contained in this document
as a result of new information, future events or otherwise.

The scientific information discussed in this news release is preliminary and
investigative. No forward-looking statement can be guaranteed and actual results
may differ materially from those Ciphergen projects. Discovery or identification
of new protein biomarkers cannot be guaranteed and movement beyond the clinical
validation process to a test that successfully screens patients for ovarian
cancer is uncertain; consequently, there can be no guarantee that the
identification of potential diagnostic markers will be successful or be an
appropriate basis for a commercially available diagnostic kit for screening
ovarian cancer.



                                      -1-




Ciphergen Biosystems, Inc.
Sue Carruthers
Investor Relations
510 505 2233

WeissComm Partners
Lori Murray
Media
415 946 1070



                                      -2-